Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm Kicks Off PI Study on FLT3 Inhibitor in US
August 9, 2017
- Growth of Global Products Outstrips Abilify Drop in Jan.-June: Otsuka
August 9, 2017
- Astellas Looks to Be First to Market in HIF-PH Inhibitor Space
August 8, 2017
- Pharmaceutical Companies Are No Longer Focusing Exclusively on Internal R&D: Oncodesign Exec
August 8, 2017
- New Heart Failure Med Hits Primary Pharmacokinetic Endpoint: Amgen Astellas
August 8, 2017
- Daiichi Sankyo Invests in Osaka Univ. Spin-Off
August 8, 2017
- PeptiDream-Shionogi-Sekisui Trio to Launch Peptide Therapeutics CMO in September
August 8, 2017
- Pfizer Recalls Wypax Tablets in Japan
August 7, 2017
- Sumitomo Dainippon Drops Napabucasin for Stomach Cancer, but Maintains 100 Billion Yen Target
August 7, 2017
- Takeda, Molecular Templates Join Hands on Cancer Therapies
August 7, 2017
- Takeda Forms R&D Partnership with Cardurion for Cardiovascular Diseases
August 4, 2017
- Partial Modification of Approval for Asacol Generics Eliminates Discrepancy in Indications
August 4, 2017
- Japan Ethical Drug Sales in April-June Down 0.8%, with Harvoni Sales Down 75.6%: QuintilesIMS
August 4, 2017
- LTL Pharma to Take Over 3 Brands from Astellas in October
August 3, 2017
- Meiji Seika Pharma to Transfer 3 Generic Brands to Its Generic Subsidiary
August 3, 2017
- Galderma Transfers Epiduo Gel to Maruho in Japan
August 3, 2017
- 3 Deaths among 85 ADRs Bayer Yakuhin Failed to Report Were Known to Employees at Symposiums
August 3, 2017
- Daiichi Sankyo Inks US$300 Million Settlement Deal over Olmesartan Product Liability Litigation in US
August 3, 2017
- Abilify Maintena Approved for Bipolar I Disorder in US
August 2, 2017
- Astellas Applies for Fidaxomicin for Infectious Enteritis in Japan
August 2, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…